Sublingual sildenafil in the treatment of erectile dysfunction: Faster onset of action with less dose

International Journal of Urology

Volumn 11, Issue 11, 2004, Pages 989-992

  Deveci, Serkan ^a   Peşkircioǧlu, Levent ^a   Aygün, Cem ^a   Tekin, M Ilteriş ^a   Dirim, Ayhan ^a   Özkardeş, Hakan ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Erectile dysfunction; Sildenafil; Sublingual; Treatment

Indexed keywords

GLUCOSE; LIPID; PLACEBO; SILDENAFIL; TESTOSTERONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COITUS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; LIPID BLOOD LEVEL; LOW DRUG DOSE; MALE; NOSE CONGESTION; PATIENT SATISFACTION; PENIS ERECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWEATING; TESTOSTERONE BLOOD LEVEL; VISUAL IMPAIRMENT;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADMINISTRATION, SUBLINGUAL; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUSHING; HEADACHE; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; SWEATING; TREATMENT OUTCOME;

EID: 9644254153     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2004.00933.x     Document Type: Article

References (11)

1. National Institutes of Health. Consensus development panel on impotence. JAMA 1993; 280: 83-90.
2. Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment J. Urol. 1999; 162: 722-5.
3. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil treatment erectile dysfunction. N. Engl. J. Med. 1998; 338: 1397-404.
4. Rosen RC, Capelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int. J. Impot. Res. 1999; 11: 319-26.
5. Eardley I, Ellis P, Boolell M, Wulff M. Onset and duration of action of sildenafil for the treatment of erectile dysfunction. Br. J. Clin. Pharmacol. 2002; 53 (Suppl.): 61-5.
6. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 2000; 38: 41-57.
7. Lim PH, Moorthy P, Benton KG. The clinical safety of Viagra. Ann. N. Y. Acad. Sci. 2002; 962: 378-88.
8. Cheitlin MD, Hutter AM Jr, Brindis RG, Kaul S, Russel RO Jr, Zusman RM. Use of sildenafil (Viagra) in patients with cardiovascular disease. Circulation 1999; 99: 168-77.
9. Muirhead GJ, Rance DJ, Walker DK, Donald K, Wastall P. Comparative human pharmacokinetics and metabolism of single dose oral and intravenous sildenafil. Br. J. Clin. Pharmacol. 2002; 53 (Suppl.): 13-21.
10. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects. Absolute bioavailability, food affects and dose proportionality. Br. J. Clin. Pharmacol. 2002; 53 (Suppl.): 55-63.
11. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int. J. Impot. Res. 1998; 10: 69-74.